News | July 23, 2025
Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Godavari Biorefineries receives patent from CNIPA
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
These medicines are essential in preventing RhD immunisation during pregnancy
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Subscribe To Our Newsletter & Stay Updated
